구조모아 (StructureMoa)항암 chemical structure spider web
방문검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-11 · 마지막 7월 31일
현재 선택: 5개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 ORR 43.6%·t½ 4 h | Datopotamab deruxtecan (Datopotamab deruxtecan) Fundación Pública Andaluza para la…·Lung Cancer ORR 79%·t½ 4.8 h | ||
|---|---|---|---|---|---|
Overview Program | Herceptin (trastuzumab) | Enhertu (trastuzumab deruxtecan) | Kadcyla (ado-trastuzumab emtansine / T-DM1) | Datopotamab deruxtecan | Disitamab Vedotin (RC48) |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Roche / Genentech | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | RemeGen |
Overview Modality | ANTIBODY | ADC | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 | Lung Cancer | HER2 |
Overview Indication | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | HER2+ breast cancer, HER2-low, gastric | HER2+ breast cancer | Breast Cancer; Metastatic Breast Cancer | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | ACTIVE |
MoA Mechanism | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. | targeting hormone receptor | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). | TROP2 on cancer cell surface and, follow | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
PK/PD Half-life | 4 h | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | 4 h | 4.8 h | ~5 days (ADC, clinical PK) |
PK/PD Species | Rat, OS in metastatic BC | Mouse, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse, Tumor response | Mouse, Rat | Mouse, ORR in HER2+ UC/gastric |
PK/PD Animal (cat.) | Rat, In vitro | Mouse, In vitro | Mouse, In vitro | Mouse, Rat, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | tumor growth inhibition | Pharmacokinetic | pd |
Toxicology Species | Rat | Cynomolgus monkey, NHP, Mouse, Rat, Hamster | Cynomolgus monkey, Mouse, Rat | Mouse, Rat, Hamster | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | — | NHP | NHP | Rat | NHP |
Toxicology Major finding | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Interstitial Lung Disease (ILD) and Pneumonitis: DATROWAY can cause severe and fatal cases of ILD | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A | Minimal | Minimal | — | N/A |
Clinical Primary efficacy | ORR 91.2% | ORR 79.7% | ORR 43.6% | ORR 79% | ORR 50% |
Clinical ORR | 91.2% | 79.7% | 43.6% (EMILIA) | 74% | ~50% in HER2+ UC |
Clinical PFS | — | NA | 9.6 mo | 4.4 | 6.9 mo |
Clinical OS | — | NA | 30.9 mo | 12.9 | — |
Clinical Result source | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT03529110 | EMILIA | ClinicalTrials.gov NCT04656652 | RC48-C009 |
Clinical Data Tier / Score | B · 95 | S · 100 | C · 90 | A · 100 | C · 89 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 | APPROVED |
Clinical Dose / schedule | — | q3w | q3w | — | q2w |
Clinical Clinical sync | 2026년 7월 31일 (3일 전) | 2026년 7월 31일 (3일 전) | 2026년 7월 31일 (3일 전) | 2026년 7월 9일 (26일 전 · 갱신 권장) | 2026년 7월 31일 (3일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-11 · 마지막 7월 31일
현재 선택: 5개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 ORR 43.6%·t½ 4 h | Datopotamab deruxtecan (Datopotamab deruxtecan) Fundación Pública Andaluza para la…·Lung Cancer ORR 79%·t½ 4.8 h | ||
|---|---|---|---|---|---|
Overview Program | Herceptin (trastuzumab) | Enhertu (trastuzumab deruxtecan) | Kadcyla (ado-trastuzumab emtansine / T-DM1) | Datopotamab deruxtecan | Disitamab Vedotin (RC48) |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Roche / Genentech | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | RemeGen |
Overview Modality | ANTIBODY | ADC | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 | Lung Cancer | HER2 |
Overview Indication | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | HER2+ breast cancer, HER2-low, gastric | HER2+ breast cancer | Breast Cancer; Metastatic Breast Cancer | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | ACTIVE |
MoA Mechanism | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. | targeting hormone receptor | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). | TROP2 on cancer cell surface and, follow | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
PK/PD Half-life | 4 h | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | 4 h | 4.8 h | ~5 days (ADC, clinical PK) |
PK/PD Species | Rat, OS in metastatic BC | Mouse, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse, Tumor response | Mouse, Rat | Mouse, ORR in HER2+ UC/gastric |
PK/PD Animal (cat.) | Rat, In vitro | Mouse, In vitro | Mouse, In vitro | Mouse, Rat, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | tumor growth inhibition | Pharmacokinetic | pd |
Toxicology Species | Rat | Cynomolgus monkey, NHP, Mouse, Rat, Hamster | Cynomolgus monkey, Mouse, Rat | Mouse, Rat, Hamster | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | — | NHP | NHP | Rat | NHP |
Toxicology Major finding | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Interstitial Lung Disease (ILD) and Pneumonitis: DATROWAY can cause severe and fatal cases of ILD | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A | Minimal | Minimal | — | N/A |
Clinical Primary efficacy | ORR 91.2% | ORR 79.7% | ORR 43.6% | ORR 79% | ORR 50% |
Clinical ORR | 91.2% | 79.7% | 43.6% (EMILIA) | 74% | ~50% in HER2+ UC |
Clinical PFS | — | NA | 9.6 mo | 4.4 | 6.9 mo |
Clinical OS | — | NA | 30.9 mo | 12.9 | — |
Clinical Result source | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT03529110 | EMILIA | ClinicalTrials.gov NCT04656652 | RC48-C009 |
Clinical Data Tier / Score | B · 95 | S · 100 | C · 90 | A · 100 | C · 89 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 | APPROVED |
Clinical Dose / schedule | — | q3w | q3w | — | q2w |
Clinical Clinical sync | 2026년 7월 31일 (3일 전) | 2026년 7월 31일 (3일 전) | 2026년 7월 31일 (3일 전) | 2026년 7월 9일 (26일 전 · 갱신 권장) | 2026년 7월 31일 (3일 전) |
추천 비교
추천 비교